Vor (VOR) falls 3.63% to Close at $15.65 on September 14

Equities Staff  |

Vor Biopharma Inc (NASDAQ: VOR) shares fell 3.63%, or $0.59 per share, to close Tuesday at $15.65. After opening the day at $16.31, shares of Vor fluctuated between $16.89 and $15.26. 177,808 shares traded hands an increase from their 30 day average of 161,831. Tuesday's activity brought Vor’s market cap to $581,312,474.

About Vor Biopharma Inc

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.

Visit Vor Biopharma Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Vor Biopharma Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Vor Biopharma Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Cross Border Money Transfer Company Remitly Seeks $7 Billion IPO Valuation
Intuit To Acquire Mailchimp for $12 Billion in Cash and Stock
Consumer Brands Association Presses White House for More Clarity on Vaccine Mandates
Freshworks Shooting for $9 Billion IPO Valuation at Top End of Filing Range
Fauci Supports COVID-19 Vaccine Mandate for All Domestic Air Travel
Jobless Claims Fall to 310,000 — Lowest in Nearly 18 Months
200 Westerners Board Qatar Airways Flight From Kabul
Pennsylvania Republican Lawmakers Launch 'Election Integrity' Investigation



Market Movers

Sponsored Financial Content